VRTX

Vertex Pharmaceuticals (VRTX) Stock Price

VRTX
$541.42
+$5.98(+1.11%)

Content updated: 2026-11-16 17:01:39

Yesterday's Close
$535.44
Today's Open
$542.62
Today's High
$542.62
Today's Low
$538.33
Volume
3.20M shares
52-Week Range
$412.50-$592.53

As of 2026-11-16 17:01:39, Vertex Pharmaceuticals (VRTX) was quoted at $541.42, a change of +$5.98 (+1.11%) from the previous close. The day's range was $538.33–$542.62, and the 52-week range was $412.50–$592.53.

Past 1W-3.09%Period Low $536.08Period High $555.99
Past 1M+4.63%Period Low $497.76Period High $568.45
Past 3M+6.92%Period Low $484.60Period High $568.45
Past 1Y+22.44%Period Low $412.27Period High $568.45

About Vertex Pharmaceuticals (VRTX)

Vertex Pharmaceuticals Incorporated is a leading biotechnology firm primarily focused on the discovery, advancement, and marketing of innovative treatments, particularly for cystic fibrosis (CF). The company offers a range of approved medications for CF patients, including SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO, which target specific mutations within the cystic fibrosis transmembrane conductance regulator gene. Additionally, they provide TRIKAFTA for individuals with CF aged six years and older who possess at least one F508del mutation. Beyond its established CF therapies, Vertex maintains a robust and diverse clinical pipeline. This includes VX-864, currently in Phase 2 for alpha-1 antitrypsin (AAT) deficiency; VX-147, also in Phase 2, addressing APOL1-mediated focal segmental glomerulosclerosis (FSGS) and other serious kidney conditions; VX-880, a potential treatment for Type 1 Diabetes undergoing Phase 1/2 trials; VX-548, a NaV1.8 inhibitor in Phase 2 for various forms of acute, neuropathic, and musculoskeletal pain; and CTX001, which is in Phase 3 development for severe sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT). The company distributes its pharmaceutical products through specialty pharmacies and distributors across the United States, while international sales are facilitated via a network of specialty distributors, retail chains, hospitals, and clinics. Vertex also engages in numerous strategic collaborations with partners such as Affinia Therapeutics, Arbor Biotechnologies, CRISPR Therapeutics, Kymera Therapeutics, Mammoth Biosciences, Moderna, Obsidian Therapeutics, Skyhawk Therapeutics, Ribometrix, Genomics plc, Merck KGaA, and X-Chem. Established in 1989, Vertex Pharmaceuticals is headquartered in Boston, Massachusetts.
Ticker / Exchanges
VRTX / NASDAQ
Industry / Sector
Biotechnology / Healthcare
CEO
Reshma Kewalramani
Headquarters
Boston,MA,US
Official Website
https://www.vrtx.com
Listing Date
1991-07-24

Recent Company Events

  • 2027-02-11
    Earnings Report · ExpectedOn 2027-02-11, the 2026/Q4 earnings report is expected to be released.

Vertex Pharmaceuticals (VRTX) Derivatives Trading

VRTXTrade
Stocks

Trade U.S., Hong Kong, Japanese, and South Korean stocks directly. Selected U.S., Hong Kong, and South Korean stocks support 24/7 trading. You hold actual shares. Corporate actions such as dividends and stock splits are handled according to market rules.

VRTXTrade
CFD

Trade stock price movements through CFDs without holding the underlying shares. CFDs support long and short positions and leveraged trading. Be aware of spreads, trading fees, overnight fees, and liquidation risk.

Vertex Pharmaceuticals (VRTX) Company Financials

Valuation and Shares

Market Cap
$136.59B
P/E Ratio (TTM)
34.65
P/B Ratio
6.53
Shares Outstanding
253.53M shares
Float Shares
252.76M shares
Dividend Yield (TTM)
0.00%

Latest Reported Financials

2026 Q3 Financials

Report Release Date: 2026-11-02

Operating Revenue (Actual)

$3.44B

Same Period Last Year: +11.85%

Earnings per Share (Actual)

$4.76

Same Period Last Year: -0.83%

Financials · Actuals

Actual Value2022/Annual2023/Annual2024/Annual2025/Annual
Revenue$8.93B$9.86B$11.02B$12.00B
Net Profit$3.32B$3.62B-$536.00M$3.95B
Operating Cash Flow$4.13B$3.53B-$493.00M$3.63B

VRTX FAQ

What is the current stock price of Vertex Pharmaceuticals (VRTX)?

x
As of 2026-11-16 17:01 (UTC+8), the latest available quote for Vertex Pharmaceuticals (VRTX) is $541.42 USD, with a change of +$5.98 USD (+1.11%) from the previous trading day's close. Current market status: Open.

Which exchange is VRTX listed on?

x

How has Vertex Pharmaceuticals stock performed over the past month?

x

What is the market cap of Vertex Pharmaceuticals?

x

What are Vertex Pharmaceuticals's latest financial results?

x

What factors may affect the stock price of Vertex Pharmaceuticals (VRTX)?

x

Other Trading Markets

Risk Warning

The stock market involves a high level of risk and price volatility. The value of your investment may increase or decrease, and you may not recover the full amount invested. Past performance is not a reliable indicator of future results. Before making any investment decisions, you should carefully assess your investment experience, financial situation, investment objectives, and risk tolerance, and conduct your own research. Where appropriate, consult an independent financial adviser.

Disclaimer

The content on this page is provided for informational purposes only and does not constitute investment advice, financial advice, or trading recommendations. Gate shall not be held liable for any loss or damage resulting from such financial decisions. Further, take note that Gate may not be able to provide full service in certain markets and jurisdictions, including but not limited to the United States of America, Canada, Iran, and Cuba. For more information on Restricted Locations, please refer to the User Agreement.